190 related articles for article (PubMed ID: 36149505)
21. Retrospective study of neuroblastoma in Chinese neonates from 1994 to 2011: an evaluation of diagnosis, treatments, and prognosis : a 10-year restrospective study of neonatal neuroblastoma.
Zhou Y; Li K; Zheng S; Chen L
J Cancer Res Clin Oncol; 2014 Jan; 140(1):83-7. PubMed ID: 24189916
[TBL] [Abstract][Full Text] [Related]
22. MYCN oncogene amplification in neuroblastoma is associated with worse prognosis, except in stage 4s: the Italian experience with 295 children.
Tonini GP; Boni L; Pession A; Rogers D; Iolascon A; Basso G; Cordero di Montezemolo L; Casale F; Pession A; Perri P; Mazzocco K; Scaruffi P; Lo Cunsolo C; Marchese N; Milanaccio C; Conte M; Bruzzi P; De Bernardi B
J Clin Oncol; 1997 Jan; 15(1):85-93. PubMed ID: 8996128
[TBL] [Abstract][Full Text] [Related]
23. Chromosome band 11q23 deletion predicts poor prognosis in bone marrow metastatic neuroblastoma patients without MYCN amplification.
Yue ZX; Xing TY; Gao C; Liu SG; Zhao W; Zhao Q; Wang XS; Jin M; Ma XL
Cancer Commun (Lond); 2019 Nov; 39(1):68. PubMed ID: 31685009
[TBL] [Abstract][Full Text] [Related]
24. Clinical research on neuroblastoma based on serum lactate dehydrogenase.
Pang QM; Li K; Ma LJ; Sun RP
J Biol Regul Homeost Agents; 2015; 29(1):131-4. PubMed ID: 25864749
[TBL] [Abstract][Full Text] [Related]
25. Diagnostic value of CT and MRI combined with serum LDH, NSE, CEA, and MYCN in pediatric neuroblastoma.
Hao J; Sang J; Xu X; Bao A
World J Surg Oncol; 2023 Aug; 21(1):251. PubMed ID: 37592273
[TBL] [Abstract][Full Text] [Related]
26. Prediction to the prognosis of children with neuroblastoma by nomogram based on the first-diagnosed inflammatory markers.
Zhang Y; Zhang C; Ma Y; Li C; Zhao Z; Peng L; Deng X; Zhou J; Wang S
Pediatr Surg Int; 2022 Nov; 39(1):17. PubMed ID: 36449181
[TBL] [Abstract][Full Text] [Related]
27. Values of serum CA125, NSE and 24-hour urine VMA in diagnosis and prediction of treatment of paediatric neuroblastoma.
Li J; Liu X; Chen M; Wang J; Wang X
Int J Clin Pract; 2021 Dec; 75(12):e14932. PubMed ID: 34606672
[TBL] [Abstract][Full Text] [Related]
28. Prognostic value of ferritin, neuron-specific enolase, lactate dehydrogenase, and urinary and plasmatic catecholamine metabolites in children with neuroblastoma.
Cangemi G; Reggiardo G; Barco S; Barbagallo L; Conte M; D'Angelo P; Bianchi M; Favre C; Galleni B; Melioli G; Haupt R; Garaventa A; Corrias MV
Onco Targets Ther; 2012; 5():417-23. PubMed ID: 23226699
[TBL] [Abstract][Full Text] [Related]
29. Correlation of modified Shimada classification with MYCN and 1p36 status detected by fluorescence in situ hybridization in neuroblastoma.
Altungoz O; Aygun N; Tumer S; Ozer E; Olgun N; Sakizli M
Cancer Genet Cytogenet; 2007 Jan; 172(2):113-9. PubMed ID: 17213019
[TBL] [Abstract][Full Text] [Related]
30. [Clinical features of neuroblastoma: an analysis of 44 children].
Zhu CG; He XL; Tang ZG; Chen KK; Zou RY; Tian X; You YL
Zhongguo Dang Dai Er Ke Za Zhi; 2020 Nov; 22(11):1193-1197. PubMed ID: 33172554
[TBL] [Abstract][Full Text] [Related]
31. N-Myc gene amplification is a major prognostic factor in localized neuroblastoma: results of the French NBL 90 study. Neuroblastoma Study Group of the Société Francaise d'Oncologie Pédiatrique.
Rubie H; Hartmann O; Michon J; Frappaz D; Coze C; Chastagner P; Baranzelli MC; Plantaz D; Avet-Loiseau H; Bénard J; Delattre O; Favrot M; Peyroulet MC; Thyss A; Perel Y; Bergeron C; Courbon-Collet B; Vannier JP; Lemerle J; Sommelet D
J Clin Oncol; 1997 Mar; 15(3):1171-82. PubMed ID: 9060561
[TBL] [Abstract][Full Text] [Related]
32. The prognostic strength of serum LDH and serum ferritin in children with neuroblastoma: A report from the International Neuroblastoma Risk Group (INRG) project.
Moroz V; Machin D; Hero B; Ladenstein R; Berthold F; Kao P; Obeng Y; Pearson ADJ; Cohn SL; London WB
Pediatr Blood Cancer; 2020 Aug; 67(8):e28359. PubMed ID: 32472746
[TBL] [Abstract][Full Text] [Related]
33. BLM germline and somatic PKMYT1 and AHCY mutations: Genetic variations beyond MYCN and prognosis in neuroblastoma.
Novak EM; Halley NS; Gimenez TM; Rangel-Santos A; Azambuja AM; Brumatti M; Pereira PL; Vince CS; Giorgi RR; Bendit I; Cristofani LM; Odone-Filho V
Med Hypotheses; 2016 Dec; 97():22-25. PubMed ID: 27876123
[TBL] [Abstract][Full Text] [Related]
34. The impact of surgical radicality on outcome in childhood neuroblastoma.
von Schweinitz D; Hero B; Berthold F
Eur J Pediatr Surg; 2002 Dec; 12(6):402-9. PubMed ID: 12548494
[TBL] [Abstract][Full Text] [Related]
35. MYCN amplification plus 1p36 loss of heterozygosity predicts ultra high risk in bone marrow metastatic neuroblastoma.
Yue ZX; Xing TY; Zhao W; Zhao Q; Wang XS; Su Y; Gao C; Liu SG; Ma XL
Cancer Med; 2022 Apr; 11(8):1837-1849. PubMed ID: 35137546
[TBL] [Abstract][Full Text] [Related]
36. Early Decline of Neuron-Specific Enolase during Neuroblastoma Chemotherapy is a Predictive Factor of Clinical Outcome.
Zhu FY; Yan J; Cao YN; Jin Y; Li J; Zhao Q
Pediatr Hematol Oncol; 2021 Sep; 38(6):543-554. PubMed ID: 34106032
[TBL] [Abstract][Full Text] [Related]
37. LDHA in Neuroblastoma Is Associated with Poor Outcome and Its Depletion Decreases Neuroblastoma Growth Independent of Aerobic Glycolysis.
Dorneburg C; Fischer M; Barth TFE; Mueller-Klieser W; Hero B; Gecht J; Carter DR; de Preter K; Mayer B; Christner L; Speleman F; Marshall GM; Debatin KM; Beltinger C
Clin Cancer Res; 2018 Nov; 24(22):5772-5783. PubMed ID: 29925504
[No Abstract] [Full Text] [Related]
38. Prediction of MYCN amplification in neuroblastoma using serum DNA and real-time quantitative polymerase chain reaction.
Gotoh T; Hosoi H; Iehara T; Kuwahara Y; Osone S; Tsuchiya K; Ohira M; Nakagawara A; Kuroda H; Sugimoto T
J Clin Oncol; 2005 Aug; 23(22):5205-10. PubMed ID: 16051962
[TBL] [Abstract][Full Text] [Related]
39. Identification of
Shao F; Wang Z; Wang S
DNA Cell Biol; 2021 Feb; 40(2):332-347. PubMed ID: 33393844
[TBL] [Abstract][Full Text] [Related]
40. Transcript signatures that predict outcome and identify targetable pathways in MYCN-amplified neuroblastoma.
Hallett RM; Seong AB; Kaplan DR; Irwin MS
Mol Oncol; 2016 Nov; 10(9):1461-1472. PubMed ID: 27599694
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
